AG-1478 (Tyrphostin AG-1478) is a highly potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with an IC50 of 3 nM. AG-1478 (Tyrphostin AG-1478) reversibly prevents rat brain Kv1.5 potassium channels (IC50 = 9.8 mM) independent of PTK activity. Additionally, AG-1478 (Tyrphostin AG-1478) also suppresses the growth of leiomyoma and myometrium cell cultures with IC50 values of 5.6 and 5.7 mM, respectively. AG-1478 (Tyrphostin AG-1478) blocke the activation of MAP kinase and strongly represses induction of fos gene expression and DNA synthesis. AG-1478 (Tyrphostin AG-1478) blocks G3 enhanced effects on cell apoptosis.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 20 mg/mL|
|Source||Sci Rep (2018). Figure 4. AG-1478|
|Cell Lines||corneal endothelial cells|
|Incubation Time||7 days|
|Results||The addition of TGF-β1 (with or without AG-1478) also generated the expression of n-cadherin at the cell membrane. The gain of n-cadherin expression following addition of TGF-β1 was confirmed using western blotting|
|Related EGFR/HER2 Products|
Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.
Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD.
Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1，which can be used to treat non-small cell lung cancer.
Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.
EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.